Form 4: Disc Medicine Director Kevin Bitterman Granted 10,000 Stock Options

Disc Medicine, Inc. Director Kevin Bitterman was granted 10,000 stock options with an exercise price of $50.86, vesting based on continued service.

Summary

• Kevin Bitterman, a Director of Disc Medicine, Inc. (IRON), was granted 10,000 stock options.
• The options have an exercise price of $50.86 per share.
• The grant date for these options was June 11, 2025.
• The options will vest upon the earlier of the Company's 2026 annual meeting of stockholders or the one-year anniversary of the grant date (June 11, 2026), contingent on Mr. Bitterman's continued service.
• The options expire on June 10, 2035.
• Mr. Bitterman disclaims beneficial ownership for Section 16 purposes, as proceeds from any sale upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, except for his pecuniary interest.

Sentiment

Score: 6

Explanation: The filing reports a standard director compensation event, which is generally neutral but can be seen as slightly positive due to alignment of interests. It contains no negative or surprising information.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term value creation.
• Standard compensation practices for directors can help attract and retain qualified board members.

Future Outlook

The stock options are subject to future vesting conditions, contingent on the director's continued service until the earlier of the Company's 2026 annual meeting or June 11, 2026.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages designed to align leadership incentives with long-term shareholder value.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a standard compensation practice across publicly traded companies, particularly in the biotech sector, to incentivize long-term commitment and performance.
• The exercise price being at market value on the grant date ($50.86) is typical for incentive stock options, ensuring that the director benefits only if the stock price appreciates.
• The vesting schedule, tied to continued service over approximately one year or until the next annual meeting, is a common approach to retain board members and ensure their ongoing engagement.

Corporate Governance

Related Party Transactions

• The disclosure that proceeds from the sale of shares upon option exercise will be transferred to Atlas Venture Life Science Advisors, LLC, with the reporting person disclaiming ownership except for pecuniary interest, indicates a pre-existing arrangement or relationship between the director and this entity.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases.
• Employees: No direct impact on employees mentioned.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders mentioned.

Next Steps

• The stock options will vest upon the earlier of the Company's 2026 annual meeting or the one-year anniversary of the grant date (June 11, 2026), subject to Kevin Bitterman's continued service.

Key Dates

Keywords

Disc Medicine, IRON, SEC Form 4, Stock Option Grant, Director Compensation, Insider Transaction, Equity Compensation, Biotechnology, Corporate Governance